Werewolf Therapeutics, Inc. — Form 8-K
Filed July 31, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 72/100
What the filing says
Werewolf Therapeutics sold its JZP898 program to Jazz Pharmaceuticals Ireland Limited for $21.0 million and repaid all K2 HealthVentures debt in Q2 2026. Cash position declined from $46.5M (Mar 31) to $22.0M (Jun 30); company projects funding through Q2 2027. The company is conducting a strategic alternatives process with Piper Sandler and expects clinical data updates on WTX-124 and WTX-330 in H2 2026.
Why this rating
Asset sale of ~53% of market cap provides runway but signals strategic pivot and potential desperation. Meaningful for survival but outcome uncertain.
See more from July 31, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.